MedTrace Logo

An Open Study Assessing the Safety and Tolerability of U3-1784

NCT02690350 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-05-16

No results posted yet for this study

Summary

The main objectives of the trial are:

* To evaluate the safety and tolerability of U3-1784 in patients with advanced solid tumours
* To determine the maximum tolerated dose (MTD) and or establish the safety and tolerability of the maximum administered dose (MAD) of U3-1784

Conditions

Interventions

DRUG

U3-1784

Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated

Sponsors & Collaborators

Principal Investigators

  • Alberto Martinez, PhD · Daiichi Sankyo UK Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02690350 on ClinicalTrials.gov